Cox-2 Inhibitors, What's Next?

Cox-2 Inhibitors After FDA/Arthritis Advisory Committee Meeting February 16-18, 2004 ...Vioxx, Celebrex, Bextra
Medical Author: William C. Shiel, Jr, FACP, FACR

The Meeting

On February 16-18, 2005, a joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA Drug Safety Committee ("committee") was convened to review the safety of COX-2 inhibitors including rofecoxib (Vioxx), celecoxib (Celebrex), and valdecoxib (Bextra) NOTE: April 7, 2005, Pfizer has agreed to suspend sales and marketing of Bextra in the U.S., pending further discussions with the with the FDA. For more information, please read the FDA press release. . The committeesreviewed the details of research studies and specifically evaluated the risks of these drugs in regard to heart attack and stroke. They also reviewed other antiinflammatory drugs including naproxen.